These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 1729534)
1. An investigation of factors influencing the in vitro induction of LAK activity against a variety of human bladder cancer cell lines. Jackson AM; Hawkyard SJ; Prescott S; Ritchie AW; James K; Chisholm GD J Urol; 1992 Jan; 147(1):207-11. PubMed ID: 1729534 [TBL] [Abstract][Full Text] [Related]
2. Effect of TNF-alpha and IFN-alpha on the proliferation and cytotoxicity of lymphokine-activated killer cells in patients with bladder cancer. Wang Z; Cheng Y; Zheng R; Qin D; Liu G Chin Med J (Engl); 1997 Mar; 110(3):180-3. PubMed ID: 9594335 [TBL] [Abstract][Full Text] [Related]
3. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines. Hermann GG; Zeuthen J; Claësson MH Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282 [TBL] [Abstract][Full Text] [Related]
4. Tretinoin or retinol enhancement of lymphokine-activated killer cell proliferation and cytotoxicity against human bladder cancer cells in vitro. Wang ZP; Zheng RL; Chen YR; Liu GD Zhongguo Yao Li Xue Bao; 1997 Nov; 18(6):522-4. PubMed ID: 10322910 [TBL] [Abstract][Full Text] [Related]
5. Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines. Wang MH; Flad HD; Böhle A; Chen YQ; Ulmer AJ Immunol Lett; 1991 Mar; 27(3):191-7. PubMed ID: 2060970 [TBL] [Abstract][Full Text] [Related]
6. Effects of reactive oxygen species on lymphokine-activated killer cells in patients with bladder cancer. Wang ZP; Chen YR; Zheng RL; Lu JZ; Wang JJ Acta Pharmacol Sin; 2002 Mar; 23(3):257-62. PubMed ID: 11918852 [TBL] [Abstract][Full Text] [Related]
7. Dissecting the immunobiological effects of Bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. Böhle A; Thanhäuser A; Ulmer AJ; Ernst M; Flad HD; Jocham D J Urol; 1993 Dec; 150(6):1932-7. PubMed ID: 8230540 [TBL] [Abstract][Full Text] [Related]
8. Intercellular adhesion molecule-1 expression by bladder cancer cells: functional effects. Campbell SC; Tanabe K; Alexander JP; Edinger M; Tubbs RR; Klein EA J Urol; 1994 May; 151(5):1385-90. PubMed ID: 7908992 [TBL] [Abstract][Full Text] [Related]
9. Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro. Thanhäuser A; Böhle A; Flad HD; Ernst M; Mattern T; Ulmer AJ Cancer Immunol Immunother; 1993 Jul; 37(2):105-11. PubMed ID: 8319241 [TBL] [Abstract][Full Text] [Related]
10. Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells. Hermann GG; Petersen KR; Steven K; Zeuthen J J Clin Immunol; 1990 Nov; 10(6):311-20. PubMed ID: 1707414 [TBL] [Abstract][Full Text] [Related]
11. Modulation by cis-diamminedichloroplatinum (II) of the susceptibilities of human T24 lined and freshly separated autologous urinary bladder transitional carcinoma cells to peripheral blood lymphocytes and lymphokine activated killer cells. Mizutani Y; Nio Y; Yoshida O J Urol; 1992 Feb; 147(2):505-10. PubMed ID: 1732632 [TBL] [Abstract][Full Text] [Related]
12. Basic fibroblast growth factor enhanced LAK cell cytotoxicities against human bladder neoplasm cells. Wang ZP; Duan GL; Chen YR; Qin DS; Liu GD; Niu HG Zhongguo Yao Li Xue Bao; 1999 Mar; 20(3):276-8. PubMed ID: 10452107 [TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor. Teichmann JV; Ludwig WD; Thiel E Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676 [TBL] [Abstract][Full Text] [Related]
14. Role of adhesion molecules in lymphokine-activated killer cell killing of bladder cancer cells: further evidence for a third ligand for leucocyte function-associated antigen-1. Jackson AM; Alexandrov AB; Prescott S; James K; Chisholm GD Immunology; 1992 Jun; 76(2):286-91. PubMed ID: 1353063 [TBL] [Abstract][Full Text] [Related]
15. Natural killer (NK) and lymphokine-activated killer (LAK) activities in a patient who recovered from cancer, and the characteristics of LAK cells generated from CD4-CD8- and CD8+ peripheral blood lymphocytes. Komatsu F; Kihara K Clin Immunol Immunopathol; 1995 Oct; 77(1):75-81. PubMed ID: 7554487 [TBL] [Abstract][Full Text] [Related]
16. In vitro effects of prostaglandin E2 or indomethacin on the proliferation of lymphokine-activated killer cells and their cytotoxicity against bladder tumor cells in patients with bladder cancer. Wang Z; Chen Y; Zheng R; Qin D; Chen X; Wang Y; Liu G Prostaglandins; 1997 Nov; 54(5):769-79. PubMed ID: 9491207 [TBL] [Abstract][Full Text] [Related]
17. Modulating effect of mitomycin or cisplatin on lymphokine-activated killer cell proliferation and antitumor activity to bladder cancer cell lines in vitro. Wang ZP; Qing DS; Shi BG; Chen YR; Liu GD Zhongguo Yao Li Xue Bao; 1998 Jul; 19(4):369-72. PubMed ID: 10375787 [TBL] [Abstract][Full Text] [Related]
18. Interleukin-7 induces differential lymphokine-activated killer cell activity against human melanoma cells, keratinocytes, and endothelial cells. Schadendorf D; Böhm M; Möller P; Grünewald T; Czarnetzki BM J Invest Dermatol; 1994 Jun; 102(6):838-42. PubMed ID: 8006445 [TBL] [Abstract][Full Text] [Related]
19. The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guéin can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligands. Miyazaki J; Kawai K; Kojima T; Oikawa T; Joraku A; Shimazui T; Nakaya A; Yano I; Nakamura T; Harashima H; Akaza H BJU Int; 2011 Nov; 108(9):1520-6. PubMed ID: 21314815 [TBL] [Abstract][Full Text] [Related]
20. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing. Wiebke EA; Custer MC; Rosenberg SA; Lotze MT J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]